I hereby certify that this correspond se is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

PATENT Docket No. 255352001800

Dated: April 2005

Signature: House Mose (Rhonda L. Mason)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mark W. J. FERGUSON et al.

Serial No.: 10/522,222

Filing Date (Int'l): July 23, 2003

For: USE OF FURIN INHIBITORS IN THE TREATMENT OF FIBROSIS AND

SCARRING (AS AMENDED)

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned


## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 1, 2, 3, 5, 7, 8, 10, 12, 15 and 17 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on November 20, 2003 (copy attached) directed to a counterpart international or foreign application.



	With t	With the application; accordingly, no fee or separate requirements are required.				
	Before the mailing of a first Office Action after the filing of a Request for Continued					
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. §					
	1.97 (	e)(1) has been provided.				
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office					
	Action on the merits; accordingly, no fee or separate requirements are required.					
	However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.					
	After receipt of a first Office Action on the merits but before mailing of a final Office					
	Action or Notice of Allowance.					
		A fee is required. A check in the amount of is enclosed.				
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached				
		to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee				
		is believed to be due.				
	After r	mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue f	ee.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
		amount of is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittate				
		form (PTO/SB/17 is attached to this submission in duplicate.)				

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 255352001800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April \_\_\_, 2005

Respectfully submitted,

Carolyn/A) Favorito

Registration No.: 39,183

MORRISON & FOERSTER LLP 3811 Valley Centre Drive, Suite 500

San Diego, California 92130

(858) 720-5195

Substitute for form 1449/PTO			· · · · · · · · · · · · · · · · · · ·	Complete if Known		
				Application Number	10/522,222	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date (Int'l)	July 23, 2003	
				First Named Inventor	Mark W. J. FERGUSON	
				Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	255352001800	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (if known)				
	1.	US-5,439,824	08-08-1995	MARK BRANTLY		
	2.	US-6,262,020	07-17-2001	JOHN LEZDEY		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document		
	3.	EP-0 968 723	01-05-2000	UNIV MANCHESTER		$\vdash$
	4.	GB-2 265 310	09-29-1993	MARK FERGUSON		$\vdash$
	5.	GB-2 324 960	11-11-1998	UNIV MANCHESTER		$\vdash$
	6.	WO-92/17206	10-15-1992	MARK FERGUSON		$\vdash$
	7.	WO-95/02579	01-26-1995	ZENECA LTD		T

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	8.	CAMERON et al., J. of Biological Chemistry (2000) 275:36741-36749	† · · · ·			
	9.	CHAN et al., PNAS USA (1992) 89:6678-6682				
	10.	DUBOIS et al., J. of Biological Chemistry (1995) 270:10618-10624				
	11.	International Search Report for PCT/GB03/03159, mailed on November 20, 2003, 6 pages				
	12.	O'KANE et al., Int. J. Biochem. & Cell Biology (1997) 29:63-78				
	13.	PEARTON et al., Experimental Dermatology (2001) 10:193-203				
	14.	SHA et al., Mol. Endocrinology (1989) 3:1090-1098				
	15.	SHAH et al., Journal of Cell Science (1995) 108:985-1002				
	16.	SHAPIRO et al., J. Histochem. Cytochem. (1997) 45:3-12	<u> </u>			
	17.	TOMLINSON et al., Methods in Molecular Biology (2003) 225:249-260				

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered
cd-244515	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.